glp 1 agonist stands for Everyone is talking about GLPs. But do you know the difference between them?⁠ ⁠ Semaglutide. Tirzepatide. Retatrutide. Three different medications. Three different mechanisms. And one thing they all have in common: they Tirzepatide stands apart by targeting

10 or 15 mg once weekly) vs Reduce to tirzepatide 5 mg once weekly vs Placebo for 52 weeks (randomized 3:3:2 at week 60) Primary outcome: Percent change in bodyweight from baseline to week 112 Results: Primary outcome (percent change in bodyweight at week 112): Tirzepatide MTD -21.9%, Tirzepatide 5 mg -16.6%, Placebo -9.9% (estimated treatment difference vs placebo -12.0% for MTD and -6.6% for 5 mg

Both cause similar side effects, primarily gastrointestinal issues like nausea, diarrhea, and constipation

Combination Approaches Future treatments might combine incretin agonists with other weight loss mechanisms like metabolism boosters, appetite suppressants working through non-incretin pathways, or fat absorption inhibitors

Significant Limitations : High costs, access barriers, tolerability issues, and sustainability concerns prevent these agents from achieving their full transformative potential at a population level

As a result, you may feel full faster and longer, so you eat less

The potential of GLP-1 agonists in weight loss has been a topic of ongoing discussion, but FDA approval for obesity has only been granted in the past decade